Description
Bremelanotide (also known by the research identifier PT-141) is a synthetic cyclic heptapeptide and a structural analogue of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring neuropeptide hormone [1]. As a member of the melanocortin receptor agonist class, it exhibits particularly high binding affinity for the melanocortin type 4 receptor (MC4R), a G protein-coupled receptor expressed broadly in the central nervous system [1][2]. Its cyclic backbone confers conformational stability relative to linear peptide analogues, a structural characteristic that has made it a useful molecular tool in receptor pharmacology research.
Investigators studying the central melanocortin system employ bremelanotide as a pharmacological probe to interrogate MC4R-mediated signaling pathways and their downstream effects on neuroendocrine and autonomic circuitry [2]. Beyond MC4R, the compound also engages other melanocortin receptor subtypes, providing researchers with a means to dissect receptor selectivity and cross-reactivity within this family. Its central nervous system penetrance following peripheral administration has positioned it as a reference compound in preclinical models examining brain circuits linked to homeostatic and motivational behavior [1][2].
Bremelanotide is supplied in lyophilized form and, when prepared at high purity and low endotoxin levels, is particularly well suited to sensitive in vitro assays and cell-based studies where bacterial contaminants could confound receptor-signaling readouts. Researchers investigating melanocortin receptor pharmacodynamics, structure-activity relationships within the melanocortin ligand family, or the broader role of MC4R in metabolic and behavioral regulation commonly include bremelanotide as a benchmark agonist in their experimental designs [2][3].
References
[1] Bremelanotide: First Approval. Drugs, 2019. https://pubmed.ncbi.nlm.nih.gov/31429064/
[2] Targeting the central melanocortin system for the treatment of metabolic disorders. Nature Reviews Endocrinology, 2023. https://pubmed.ncbi.nlm.nih.gov/37365323/
[3] Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of Women's Health, 2022. https://pubmed.ncbi.nlm.nih.gov/35147466/
